Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer
Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer
复制标题
DOI：
10.1158/1055-9965.epi-05-0035
复制
发表时间：
2005-05-01
影响因子：
3.8
通讯作者：
Finn, OJ
中科院分区：
文献类型：
--
作者：
Cramer, DW;Titus-Ernstoff, L;Finn, OJ
许多癌症，包括卵巢癌，过度表达上皮粘蛋白（MUC 1），并促进抗MUC 1抗体，这可能与更有利的预后相关。进一步说，卵巢癌的风险可能会降低预先存在的MUC 1特异性免疫。我们测量了705名对照妇女的抗MUC 1抗体，确定了预测抗体的事件，并通过比较对照组与668例卵巢癌病例中产生抗体的事件的概况来估计卵巢癌风险。预测抗体的因素包括口服避孕药的使用，乳腺炎，骨折或骨质疏松症，盆腔手术，不使用滑石粉在生殖器卫生，并在较小程度上宫内节育器的使用和当前吸烟。具有抗MUC 1抗体的可能性显著增加，从0或1个条件的妇女的24.2%增加到5个或更多条件的妇女的51.4%。通过相同的事件指数，卵巢癌的风险与易患抗MUC 1抗体的疾病数量呈负相关。与经历0或1起事件相比，卵巢癌的校正风险随着相对风险的增加而逐渐降低（和95%置信限）为0.69（0.52-0.92）、0.64（0.47-0.88）、0.49（0.34-0.72）和0.31（0.16-0.61），分别为2，3，4和5个或更多与抗体存在相关的事件的女性（P趋势< 0.0001）。我们的结论是，卵巢癌的几个传统的和新的危险因素可以解释为他们的能力，通过MUC 1暴露于各种MUC 1阳性组织的炎症或激素过程的背景下的免疫识别，诱导MUC 1免疫。
Many cancers, including ovarian, overexpress epithelial mucin (MUC1) and promote anti-MUC1 antibodies that may correlate with more favorable prognosis. By extension, risk for ovarian cancer might be reduced by preexisting MUC1-specific immunity. We measured anti-MUC1 antibodies in 705 control women, identified events predicting antibodies, and estimated ovarian cancer risk by comparing profiles of events generating antibodies in controls with those in 668 ovarian cancer cases. Factors predicting antibodies included oral contraceptive use, breast mastitis, bone fracture or osteoporosis, pelvic surgeries, nonuse of talc in genital hygiene, and to a lesser extent intrauterine device use and current smoking. There was a significant increase in the likelihood of having anti-MUC1 antibodies from 24.2% in women with 0 or 1 condition, to 51.4% in those with five or more conditions. By the same index of events, the risk for ovarian cancer was inversely associated with number of conditions predisposing to anti-MUC1 antibodies. Compared with having experienced 0 or 1 event, the adjusted risk for ovarian cancer decreased progressively with relative risks (and 95% confidence limits) of 0.69 (0.52-0.92), 0.64 (0.47-0.88), 0.49 (0.34-0.72), and 0.31 (0.16-0.61), respectively for women with two, three, four, and five or more events related to the presence of antibodies (P-trend < 0.0001.) We conclude that several traditional and new risk factors for ovarian cancer may be explained by their ability to induce MUC1 immunity through exposure of MUC1 to immune recognition in the context of inflammatory or hormonal processes in various MUC1-positive tissues.